You might not have heard about tregalizumab before! Tregalizumab has
been developed as a biomarker to monitor response to biologics. Wikipedia is quite taciturn on
tregalizumab: “Tregalizumab is an
immunomodulator. It binds to CD4.” http://en.wikipedia.org/wiki/Tregalizumab
The abstract at the ACR meeting puts it this way: “Tregalizumab
is a humanized, agonistic monoclonal antibody which binds to a unique epitope
of CD4, and induces Treg-specific activation and suppresses CD4 and CD8
effector cell proliferation and activity in vitro.”
E. Dokoupilova and
colleagues presented the following study [1412]: “Use Of a Biologic Marker For An Integrated Pharmacodynamic and Clinical
Analysis To Inform Further Clinical Development, Including Dose Selection For
The Phase 2b Trial - Treat 2b - Of Tregalizumab In Rheumatoid
Arthritis.” Conclusion: “Interim efficacy and safety data from
the Phase 2b Study 979, combined with data from previous RCTs, indicated the
feasibility and tolerability of this therapeutic approach. […] The available
data support further development of tregalizumab.”
The abstract informs us of very
early data, so I think we have to wait for more, stressable data. We would be
lucky to have another mode of action.
No comments:
Post a Comment